Navigation Links
Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
Date:11/24/2008

ear efficacy in this difficult type of osteoarthritis patients and showing the same GI adverse event rate as placebo. The blood pressure data are consistent with previous studies and we are keenly awaiting the important results of the pre-defined statistical analysis in the next few weeks, following the pooling of the 301, 302 and 303 blood pressure data. We are confident that these results will clearly demonstrate naproxcinod's non-detrimental blood pressure profile, in contrast to naproxen."

Design and results of the 303 study

The 303 study was a 13-week, double-blind, placebo and naproxen controlled trial in patients with OA of the hip. 810 patients were enrolled at 120 clinical centers in the United States, Canada and Europe. Eligible patients had a diagnosis of primary osteoarthritis of the hip of at least three months in duration and were randomized on a 2:2:1 basis to receive naproxcinod 750 mg bid, placebo bid and naproxen 500 mg bid, respectively.

The three co-primary endpoints of the study compared the efficacy of naproxcinod 750 mg bid to placebo, in terms of the mean change between baseline and week 13 in the following scores: the WOMAC(TM) pain subscale, the WOMAC(TM) function subscale and the subject's overall rating of disease status. The results demonstrated that naproxcinod was superior to placebo with high statistical significance (p<0.001) on all three of these co-primary endpoints. These were the same endpoints as those used in the 301 and 302 phase 3 studies. No statistical comparison was made between naproxen 500 mg bid and the other two arms on the efficacy endpoints, due to the 2:2:1 randomization in the study, although numerical data show that naproxcinod 750 mg bid behaved in a similar fashion to naproxen 500 mg bid on these efficacy scores. NicOx entered into a full-service agreement for the conduct of the 303 study with Covance Inc., a global contract research organizati
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

13611

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
4. CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on November 3, 2008
5. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
6. Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvoxs Patient Share in the Treatment of Nosocomial Pneumonia
7. NewCardio Announces Positive Results From Third Clinical Validation Study
8. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
9. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
10. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
11. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... December 15, 2014 ... 19. und 20. Februar sind alle akkreditierten ... MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, ... geben, die neue profitablen Unternehmensdienstleistungen, die für ...
(Date:12/15/2014)... Research and Markets , ... has announced the addition of the "Cardiac Guidewires ... their offering. Global Guidewires sector is projected to ... America accounts for nearly 35% (2015) of ... claims approximately 25% (2018). Asia-Pacific ...
(Date:12/15/2014)... and BRIDGEWATER, N.J. , Dec. ... and Sanofi US (EURONEXT: SAN and NYSE: SNY) are ... to launch Cholesterol Counts , an awareness program ... their numbers, and the risks associated with high LDL-C ... www. CholesterolCounts .com to take a brief poll ...
Breaking Medicine Technology:Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
... 2012  Genalyte, Inc., a life sciences company developing ... completion of an $11.8 million Series B financing.  ... and private investors from Genalyte,s Series A round ... to use the new funds primarily for commercialization ...
... ThermoGenesis Corp. (NASDAQ: KOOL ), a ... and store adult stem cells, said today that its ... first company in China to receive accreditation from the ... is an international, not-for-profit association representing nearly 2,000 institutions ...
Cached Medicine Technology:Genalyte, Inc. Completes $12 Million Series B Financing to Commercialize Its Maverick™ Next-Generation Multiplexing Platform 2Genalyte, Inc. Completes $12 Million Series B Financing to Commercialize Its Maverick™ Next-Generation Multiplexing Platform 3ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China 2ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Host Investor Conference Call on Thursday, May 14, ... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ... development and commercialization of medically important, novel pharmaceutical ... renal disease and cancer (the "Company"), today announced ...
... finds , , WEDNESDAY, May 13 (HealthDay News) -- ... symptoms of bronchiolitis -- a virus-triggered condition that causes ... may reduce the risk of hospitalization by more than ... babies back to normal feeding sooner than either treatment ...
... Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: ... therapeutics for disease indications with large markets, today announced ... 2009., Selected Highlights, ... fiscal 2009 and up to the date of this ...
... start of dementia , , WEDNESDAY, May 13 (HealthDay News) ... the risk for developing Alzheimer,s disease in older people. ... well as complex physiological testing, may not be practical for ... fairly easy, such as age and mental status exams. We ...
... ROCHESTER, N.Y., May 13 A multi-million dollar ... to launch the University of Rochester ... recognized, comprehensive center for investigating and treating neurological ... dystrophy, stroke, and trauma to the brain and ...
... ANGELES, May 13 Runners, cyclists, fans and anyone interested ... the Memorial Day weekend leading up to the 24th Los ... Memorial Day, May 25. Coming up:>> Saturday, May 23: Run/Ex/09 ... Run/Ex/09, will open in the South Hall of the Los ...
Cached Medicine News:Health News:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results 2Health News:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results 3Health News:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results 4Health News:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results 5Health News:Combo Treatment Eases Wheezing in Babies 2Health News:Combo Treatment Eases Wheezing in Babies 3Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 2Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 3Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 4Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 5Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 6Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 7Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 8Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 9Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 10Health News:15-Point Test Gauges Alzheimer's Risk 2Health News:$10 Million Gift to Transform Neuromedicine at URMC 2Health News:$10 Million Gift to Transform Neuromedicine at URMC 3Health News:$10 Million Gift to Transform Neuromedicine at URMC 4Health News:$10 Million Gift to Transform Neuromedicine at URMC 5Health News:Full Calendar of Activities for 24th Los Angeles Marathon This Memorial Day Weekend 2
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Each slide contains Giardia lamblia trophozoites applied as a mono-layer to the side....
... wells: a positive control containing ... in simulated sputum and a ... subsp. albus ATCC ® 3004 ... Control Slides should be stained ...
... With 384 Well Plate Capability The ... the original Equalizerexpandable and equal tip spacing, choice ... calibration capabilities. In addition, this model allows you ... for loading and accessing many gels and for ...
Medicine Products: